Palandri Francesca, Iacobucci Ilaria, Castagnetti Fausto, Testoni Nicoletta, Poerio Angela, Amabile Marilina, Breccia Massimo, Intermesoli Tamara, Iuliano Francesco, Rege-Cambrin Giovanna, Tiribelli Mario, Miglino Maurizio, Pane Fabrizio, Saglio Giuseppe, Martinelli Giovanni, Rosti Gianantonio, Baccarani Michele
Department of Hematology and Oncology "L. and A. Seràgnoli", St. Orsola-Malpighi University Hospital, via Massarenti 9, 40138 Bologna, Italy.
Haematologica. 2008 May;93(5):770-4. doi: 10.3324/haematol.12265. Epub 2008 Mar 26.
In 2004, we reported the short-term results of a multicentric, phase 2 study of imatinib 400 mg daily and pegylated interferon-alpha in the treatment of 76 early chronic phase Philadelphia-positive chronic myeloid leukemia patients. In this report, we update the results with an observation time of five years. After two years of treatment, all but 10 patients (13%) had discontinued pegylated interferon-alpha. The complete cytogenetic response rate at five years was 87%, and 94% of complete cytogenetic responders maintained the complete cytogenetic response after five years. All but one complete cytogenetic response also achieved a major molecular response. These data confirm the excellent response to imatinib front-line and the stability of the complete cytogenetic response. Any possible additional benefit of the combination with interferon-alpha remains uncertain, due to low patient compliance.
2004年，我们报告了一项多中心2期研究的短期结果，该研究使用每日400毫克伊马替尼和聚乙二醇化干扰素-α治疗76例早期慢性期费城染色体阳性慢性髓性白血病患者。在本报告中，我们将观察时间延长至五年并更新结果。治疗两年后，除10例患者（13%）外，所有患者均停用了聚乙二醇化干扰素-α。五年时的完全细胞遗传学缓解率为87%，94%的完全细胞遗传学缓解者在五年后维持了完全细胞遗传学缓解。除1例完全细胞遗传学缓解者外，其余所有患者均实现了主要分子学缓解。这些数据证实了伊马替尼一线治疗的优异疗效以及完全细胞遗传学缓解的稳定性。由于患者依从性低，与干扰素-α联合使用可能带来的任何额外益处仍不确定。
